Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far - Université d'Angers Accéder directement au contenu
Article Dans Une Revue International Journal of Nanomedicine Année : 2019

Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far

Résumé

Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Phase III clinical trial to date has reported survival benefits relative to standard treatment. There are several possible reasons for this limited efficacy, including VEGF-independent angiogenesis, induction of tumor invasion, and inefficient antiangiogenic factor delivery to the tumor. Efforts have been made to overcome these limitations by identifying new angiogenesis inhibitors that target angiogenesis through different mechanisms of action without inducing tumor invasion, and through the development of viral and nonviral delivery methods to improve antiangiogenic activity. Herein, we describe the nonviral methods, including convection-enhanced delivery devices, implantable polymer devices, nanocarriers, and cellular vehicles, to deliver antiangiogenic factors. We focus on those evaluated in intracranial (orthotopic) animal models of GB, the most relevant models of this disease, as they reproduce the clinical scenario of tumor progression and therapy response encountered in GB patients.

Fichier principal
Vignette du fichier
clavreul_2019_nanocarriers_and_non_viral_methods_for_deliveringantiangiogenic_factors_for_glioblastoma_theray_the_story_so_far.pdf (7.61 Mo) Télécharger le fichier
Origine : Accord explicite pour ce dépôt
Loading...

Dates et versions

hal-02616075 , version 1 (24-05-2020)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Anne Clavreul, Milad Pourbaghi-Masouleh, Emilie Roger, Philippe Menei. Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far. International Journal of Nanomedicine, 2019, 14, pp.2497-2513. ⟨10.2147/IJN.S194858⟩. ⟨hal-02616075⟩
74 Consultations
91 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More